Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3194-4
Abstract: Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF). Unfortunately, many patients must discontinue ruxolitinib, at which time treatment options are not well defined. In this study,… read more here.
Keywords: salvage treatment; treatment; salvage; ruxolitinib discontinuation ... See more keywords